DOCS
Doximity, Inc.Price & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| active prescribers | 800,000 | Q4 FY2026 | — |
| Adjusted EBITDA non-GAAP | $357.8M | Fiscal Year 2026 | — |
|
|
|||
| Free cash flow | $317.5M | Fiscal Year 2026 | — |
|
|
|||
| Operating cash flow | $109.5M | Q4 FY2026 | — |
| adjusted EBITDA margin non-GAAP | 60.2% | fiscal 2026 third quarter | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DOCS
this stock
Doximity, Inc.
|
$4.07B | -49.7% | +13.1% | 22.7 | 10.8% |
|
VEEV
Veeva Systems Inc
|
$31.52B | -13.2% | +28.1% | 34.4 | 4.6% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$15.67B | -9.4% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$13.31B | +82.3% | -0.4% | 49.0 | 6.6% |
|
TEM
Tempus AI, Inc.
|
$10.28B | -3.0% | +65.8% | — | 18.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DOCS | +2.6% | +7.6% | -44.1% | +7.3% | -49.7% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | +1.4% | +7.8% | -54.3% | +6.3% | -60.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.